Drugs in the Pipeline
ARCHES (NCT02677896) is a randomized, double-blind placebo-controlled, multinational trial that assigned 1150 patients with mHSPC to either Xtandi 160mg daily or placebo plus ADT (luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or bilateral orchiectomy).
News
"We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC," said Michael Cookson, MD, member of the 2018 amendment panel.
News
The Task Force recommends that for men 55 to 69 years of age, the decision to undergo prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one.
News
Erleada is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer.
News
The FDA approval was supported by results from the Phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled LATITUDE trial (N=1,199) which evaluated Zytiga 1000mg once daily in combination with prednisone 5mg once daily vs placebo in newly diagnosed, metastatic high-risk CSPC patients who had not received prior cytotoxic chemotherapy.
News
Nearly 7,000 Italian men participating in the Moli-sani epidemiological study aged ≥50 years were monitored for an average of 4.25 years.
News
The USPSTF performed a systematic review of the existing evidence and concluded that the potential benefits and harms of prostate-specific antigen (PSA)-based screening are "closely balanced" in men aged 55-69 years.
News
The Food and Drug Administration (FDA) has reported a shortage of Etopophos (etoposide phosphate; Bristol-Myers Squibb) Injection as of September 16, 2016.
News
Researchers from Brigham and Women's Hospital concluded that patients' race significantly affects their longevity by increasing mortality risk after receiving androgen deprivation therapy (ADT).
News
The Food and Drug Administration (FDA) has approved Jatenzo (testosterone undecanoate; Clarus Therapeutics) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.
